Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia

Jazz Pharmaceuticals

7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for injection) for the treatment of adults with newly diagnosed therapy related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes.

The approval of Vyxeos is based on results from a Phase 3 trial of 309 adult patients, aged 60-75, with newly diagnosed herapy related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes.

Read Jazz Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder